Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022–2024) - Top-Institutions - MDSpire

Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022–2024)

  • By

  • Pablo Ryan

  • Juan Berenguer

  • Luis Ramos-Ruperto

  • Mar Vera

  • Luz Martín-Carbonero

  • Leire Pérez-Latorre

  • Ignacio De los Santos

  • Adriana Pinto

  • María J Vivancos

  • Eva Orviz

  • Beatriz Álvarez

  • José Sanz

  • Pilar Ruiz-Seco

  • Rafael Torres

  • Beatriz Brazal

  • Marta De Miguel

  • Beatriz López-Centeno

  • Inmaculada Jarrín

  • Salvador Resino

  • José M Bellón

  • Juan González-García

  • GeSIDA 12121-CoRIS Cohort 08_2021 ATHENS study group

  • November 6, 2025

  • 0 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • HIV/AIDS Research

  • #2

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Public Health

  • #3

    Institut Pasteur
    Institut Pasteur

    Paris, Île-de-France

    Key Differentiators

    • Virology
    • Infectious Diseases
    • Epidemiology

  • #4

    University College London (UCL) Institute of Epidemiology & Health Care
    University College London (UCL) Institute of Epidemiology & Health Care

    London, England

    Key Differentiators

    • Epidemiology
    • Infectious Diseases
    • Public Health

  • #5

    Hospital Clínic de Barcelona
    Hospital Clínic de Barcelona

    Barcelona, Catalonia

    Key Differentiators

    • Infectious Diseases
    • Hepatology
    • Epidemiology

Original Source(s)

Epidemiology and Risk Factors for HCV Infection Among MSM With or at Risk of HIV in Madrid (2022–2024)

  • by Pablo Ryan, Juan Berenguer, Luis Ramos-Ruperto, Mar Vera, Luz Martín-Carbonero, Leire Pérez-Latorre, Ignacio De los Santos, Adriana Pinto, María J Vivancos, Eva Orviz, Beatriz Álvarez, José Sanz, Pilar Ruiz-Seco, Rafael Torres, Beatriz Brazal, Marta De Miguel, Beatriz López-Centeno, Inmaculada Jarrín, Salvador Resino, José M Bellón, Juan González-García, GeSIDA 12121-CoRIS Cohort 08_2021 ATHENS study group

  • November 6, 2025

Related Content

Impact of Viral Infections on Immune Microenvironment Alterations and Responses to Immune Checkpoint Therapy: Interactions Between Infection, Immunity, and Cancer

Telomere Length as a Potential Biomarker for Hepatocellular Carcinoma: A Comparative Analysis of Patients with HCV Treated with Direct Antiviral Agents

Retrospective Analysis of Direct-Acting Antiviral Treatment Outcomes in Hepatitis C Patients in Saudi Arabia Before and After Therapy